---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-26-000034"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2026-09-15T11:06:34+00:00"
generated_at: "2026-09-15T11:10:17.718543+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rademikibart Phase 2 asthma: FEV1 up 130mL (p=0.023); treatment failure down 66% (p=0.153)

## Summary
- FEV1 at Day 7 improved 250 mL vs 120 mL placebo (130 mL delta, p=0.023), a statistically significant key secondary.
- Treatment failure within 28 days reduced ~66% vs placebo but missed significance (p=0.153) due to lower-than-expected event rate.
- ED/unscheduled visits for worsening asthma cut 50% vs placebo; safety comparable, 1 SAE rademikibart vs 3 placebo.
- 160 patients (79 rademikibart 600mg, 81 placebo); FDA Phase 3 alignment planned; COPD (CBP-201-207) data due later this month.

## SEC filing metadata
- accession: 0001835268-26-000034
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2026-09-15T11:06:34+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000034/0001835268-26-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000034/cntb-20260915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-26-000034
- JSON: https://secwatch.observer/filing/0001835268-26-000034.json
- Plain text: https://secwatch.observer/filing/0001835268-26-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.